We also report a comparable frequency of loss of the CDKN2A gene (25% in our tumour group) to those described by Bui and colleagues by analysing the Foundation One Medicine database (n = 372, 21% of cases) [15] and to that reported in the TCGA Adult Soft Tissue Sarcoma study (n = 44, 20.5% of cases) [10]. The gene discussed is CDKN2A; the disease is neoplasm.